The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

PLANTAR FASCIITIS RELIEF SHOE INSERT: With the widest and deepest heel cradle design, the heel and feet high quality adaption, FeelLife protects your heel during the heavy impact during running or ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide) follows the publication of the results of the phase 3 ARASENS trial in the New England ...

Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study.

(UroToday.com) The 2025 AUA annual meeting featured an advanced prostate cancer session and a presentation by Dr. Neal Shore discussing ultra-low PSA response (<0.02 ng/mL) with darolutamide plus ADT ...

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA. According to Adam B. Weiner, MD, a urologist at Cedars-Sinai ...

This webpage is supported through an unrestricted educational grant from Bayer. Bayer is not involved in content development and the views expressed represent those of the patient and physician ...